Generex Posts Slides, Script & Recording of Invest
Post# of 36568
(Total Views: 231)
Posted On: 12/04/2018 8:43:47 AM
Generex Posts Slides, Script & Recording of Investor Conference Call
Business Wire
Business WireDecember 4, 2018, 8:30 AM EST
MIRAMAR, Fla.--(BUSINESS WIRE)--
Slide Deck and transcript available for download
https://www.generex.com/investor
Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (“Generex”) announces that the company has posted the slides and the transcript of the December 3, 2018 investor conference call on the company website in the Investors section at https://www.generex.com/investor.
“We would like to thank our investors and other interested parties for participating in the Generex investor conference call yesterday,” said Joe Moscato, Generex CEO. “Following our presentations, I trust that the investment community has a better appreciation of our vision and strategic plan to build Generex into a next generation, integrated healthcare holding company. As discussed on the call, Generex is focused on generating revenue and operating capital through NuGenerex Distribution Solutions (NDS) that has been created by our acquisition of a management services organization (MSO), a network of pharmacies, a clinical laboratory, and a DME company, DME-IQ. We plan to expand our MSO network services in up to 27 states where we are working to contract and/or purchase ancillary service providers for pharmacy, laboratories, and DME, and we are partnering with physicians in those states to promote patient centric care. We also plan to add a significant acquisition to our network that includes a nation-wide direct to patient pharmacy business, offering significant revenues and enabling a rapid growth trajectory for NDS.”
Mr. Moscato continued, “In addition to our MSO and pharmacy acquisitions, we have acquired two exciting companies in the wound care & regenerative medicine space, Regentys and Olaregen, and will be launching Excellagen®, our first product from Olaregen in early 2019. Excellagen® is FDA cleared for the treatment of 17 wound care indications, including surgical incisions, diabetic ulcers and pressure ulcers (bed sores), trauma wounds and burns, among others in the $20 billion wound care market. It is exciting that Generex, led by the experienced commercial team at Olaregen, will be launching our first drug through our MSO and pharmacy networks in the highly valuable wound care market in 2019, and we look forward to reporting on our commercial results with Excellegen®.”
Business Wire
Business WireDecember 4, 2018, 8:30 AM EST
MIRAMAR, Fla.--(BUSINESS WIRE)--
Slide Deck and transcript available for download
https://www.generex.com/investor
Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (“Generex”) announces that the company has posted the slides and the transcript of the December 3, 2018 investor conference call on the company website in the Investors section at https://www.generex.com/investor.
“We would like to thank our investors and other interested parties for participating in the Generex investor conference call yesterday,” said Joe Moscato, Generex CEO. “Following our presentations, I trust that the investment community has a better appreciation of our vision and strategic plan to build Generex into a next generation, integrated healthcare holding company. As discussed on the call, Generex is focused on generating revenue and operating capital through NuGenerex Distribution Solutions (NDS) that has been created by our acquisition of a management services organization (MSO), a network of pharmacies, a clinical laboratory, and a DME company, DME-IQ. We plan to expand our MSO network services in up to 27 states where we are working to contract and/or purchase ancillary service providers for pharmacy, laboratories, and DME, and we are partnering with physicians in those states to promote patient centric care. We also plan to add a significant acquisition to our network that includes a nation-wide direct to patient pharmacy business, offering significant revenues and enabling a rapid growth trajectory for NDS.”
Mr. Moscato continued, “In addition to our MSO and pharmacy acquisitions, we have acquired two exciting companies in the wound care & regenerative medicine space, Regentys and Olaregen, and will be launching Excellagen®, our first product from Olaregen in early 2019. Excellagen® is FDA cleared for the treatment of 17 wound care indications, including surgical incisions, diabetic ulcers and pressure ulcers (bed sores), trauma wounds and burns, among others in the $20 billion wound care market. It is exciting that Generex, led by the experienced commercial team at Olaregen, will be launching our first drug through our MSO and pharmacy networks in the highly valuable wound care market in 2019, and we look forward to reporting on our commercial results with Excellegen®.”
(0)
(0)